Cabinet Barny advised Enterome on the conclusion of a global licensing, co-development and co-promotion agreement with Takeda for the treatment of Crohn’s disease.

Enterome will receive an upfront payment of $50 million and a commitment from Takeda to make a future equity investment in the Company. Enterome is also eligible to receive up to $640 million for achieving specified clinical development, regulatory and commercial milestones with Enterome's drug candidate EB8018.

Click here for more information.

Cabinet Barny advised Domain Therapeutics on the assignment of its intellectual property rights towards Foliglurax in the course of Lundbeck's acquisition of Prexton Therapeutics.

Cabinet Barny advised ILTOO PHARMA on the conclusion of a license option agreement with Servier for the clinical development and commercialization of the ILT-101 drug candidate for the treatment of autoimmune diseases.

Click here for more information.

Cabinet Barny advised Domain Therapeutics on the conclusion of a collaboration agreement with Pfizer.

Click here for more information.